Last reviewed · How we verify
Placebo matching with Metformin XR
Placebo matching with Metformin XR is a Small molecule drug developed by Bristol-Myers Squibb. It is currently FDA-approved for Clinical trial control for studies evaluating Metformin XR efficacy and safety.
This is a placebo formulation matched to Metformin XR for use as a control in clinical trials, containing no active pharmaceutical ingredient.
This is a placebo formulation matched to Metformin XR for use as a control in clinical trials, containing no active pharmaceutical ingredient. Used for Clinical trial control for studies evaluating Metformin XR efficacy and safety.
At a glance
| Generic name | Placebo matching with Metformin XR |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Placebo matching with Metformin XR refers to an inert tablet or capsule formulated to match the appearance, taste, and physical characteristics of Metformin XR (extended-release metformin) for use in blinded clinical trials. It allows researchers to compare the effects of active Metformin XR against an inactive control while maintaining blinding of study participants and investigators. This is a regulatory and research tool rather than a therapeutic agent.
Approved indications
- Clinical trial control for studies evaluating Metformin XR efficacy and safety
Common side effects
Key clinical trials
- Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction (PHASE2)
- Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes (PHASE4)
- Efficacy and Tolerability of Adjunct Metformin for Multibacillary Leprosy (PHASE2)
- Metformin for Fibromyalgia Symptoms (INFORM Trial) (PHASE2)
- Safety and Pharmacokinetics Study of CPL207280 Compound in Healthy Volunteers. (PHASE1)
- A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296) (PHASE1)
- Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes (PHASE4)
- Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matching with Metformin XR CI brief — competitive landscape report
- Placebo matching with Metformin XR updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI
Frequently asked questions about Placebo matching with Metformin XR
What is Placebo matching with Metformin XR?
How does Placebo matching with Metformin XR work?
What is Placebo matching with Metformin XR used for?
Who makes Placebo matching with Metformin XR?
What development phase is Placebo matching with Metformin XR in?
Related
- Manufacturer: Bristol-Myers Squibb — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Clinical trial control for studies evaluating Metformin XR efficacy and safety
- Compare: Placebo matching with Metformin XR vs similar drugs
- Pricing: Placebo matching with Metformin XR cost, discount & access